These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 17443935)

  • 1. The use of transdermal rotigotine in a patient with advanced Parkinson's disease and dysphagia.
    Christie J
    Palliat Med; 2007 Mar; 21(2):163-4. PubMed ID: 17443935
    [No Abstract]   [Full Text] [Related]  

  • 2. Rotigotine Transdermal Patch Improves Swallowing in Dysphagic Patients with Parkinson's Disease.
    Hirano M; Isono C; Sakamoto H; Ueno S; Kusunoki S; Nakamura Y
    Dysphagia; 2015 Aug; 30(4):452-6. PubMed ID: 25966655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rotigotine: Parkinson's disease: a step backward.
    Prescrire Int; 2008 Apr; 17(94):60. PubMed ID: 18516813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease.
    Zareba G
    Drugs Today (Barc); 2006 Jan; 42(1):21-8. PubMed ID: 16511608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K; Lyons KE
    Pharmacotherapy; 2009 Dec; 29(12):1452-67. PubMed ID: 19947805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Night-time use of rotigotine in advanced Parkinson's disease.
    Canesi M; Mariani CB; Isaias IU; Pezzoli G
    Funct Neurol; 2010; 25(4):201-4. PubMed ID: 21388580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
    Splinter MY
    Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rotigotine transdermal patches (Neupro) for the treatment of Parkinson's disease.
    Chatsis V
    Issues Emerg Health Technol; 2008 Feb; (112):1-6. PubMed ID: 18354859
    [No Abstract]   [Full Text] [Related]  

  • 9. Transdermal rotigotine (Neupro) for Parkinson's disease.
    Med Lett Drugs Ther; 2007 Aug; 49(1268):69-70. PubMed ID: 17712291
    [No Abstract]   [Full Text] [Related]  

  • 10. Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease.
    Naidu Y; Chaudhuri KR
    Expert Opin Drug Deliv; 2007 Mar; 4(2):111-8. PubMed ID: 17335409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome.
    Kenney C; Jankovic J
    Expert Opin Pharmacother; 2007 Jun; 8(9):1329-35. PubMed ID: 17563266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of rotigotine transdermal system on non-motor symptoms in Parkinson's disease: an overview.
    Zesiewicz TA; Martinez-Martin P
    Expert Rev Neurother; 2013 Dec; 13(12):1329-42. PubMed ID: 24236902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of rotigotine in individuals with Parkinson's disease aged 75 and older.
    Fasano A; Guidubaldi A; De Nigris F; Bentivoglio AR
    J Am Geriatr Soc; 2011 Dec; 59(12):2386-7. PubMed ID: 22188090
    [No Abstract]   [Full Text] [Related]  

  • 14. [Dopamine receptor agonists: new forms and new possibilities in the treatment of Parkinson's disease].
    Katunina EA; Titova NV; Bezdolny YN; Shykkerimov RK; Gasanov MG; Burd SG; Lebedeva AV; Boiko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(5):34-40. PubMed ID: 26356158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacology sheet. Transdermal Rotigotine (Neupro)].
    J Pharm Belg; 2010 Jun; (2):49-50. PubMed ID: 20623986
    [No Abstract]   [Full Text] [Related]  

  • 16. Rotigotine effect on sleep in a de novo Parkinson's Disease patient affected by periodic limb movement disorder.
    Liguori C; Placidi F; Stefani A; Mercuri NB; Marciani MG; Stanzione P; Pierantozzi M
    Parkinsonism Relat Disord; 2015 Dec; 21(12):1476-8. PubMed ID: 26578038
    [No Abstract]   [Full Text] [Related]  

  • 17. [Rotigotine. One patch, two targets!].
    Sabourin G
    Perspect Infirm; 2013; 10(4):60. PubMed ID: 24046901
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of the rotigotine transdermal patch versus oral levodopa on swallowing in patients with Parkinson's disease.
    Hirano M; Isono C; Fukuda K; Ueno S; Nakamura Y; Kusunoki S
    J Neurol Sci; 2019 Sep; 404():5-10. PubMed ID: 31323520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rotigotine may control drooling in patients with Parkinson's Disease: Preliminary findings.
    Schirinzi T; Imbriani P; D'Elia A; Di Lazzaro G; Mercuri NB; Pisani A
    Clin Neurol Neurosurg; 2017 May; 156():63-65. PubMed ID: 28342306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rotigotine in the treatment of Parkinson's disease. A study on a sample of 150 patients].
    Ruiz-Huete C; Bermejo PE; Terrón C; Anciones B
    Rev Neurol; 2008 Mar 1-15; 46(5):257-60. PubMed ID: 18351563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.